Floatz logo

DAB389IL-2

Lymphoma, T-Cell, Cutaneous

Eisai Inc.Phase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

62 Active assets in the Lymphoma, T-Cell, Cutaneous cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Cyclophosphamide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 2BBB
Bexarotene
Case Comprehensive Cancer Center
Phase 4BBB
Fludarabine
National Cancer Institute (NCI)
Phase 2BBB

View all 50 →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →